September 19, 2017 / 4:54 PM / a month ago

BRIEF-Lexicon Pharmaceuticals gets European Commission's approval for Xermelo

Sept 19 (Reuters) - Lexicon Pharmaceuticals Inc:

* European Commission approves Xermelo (Telotristat Ethyl) for the treatment of Carcinoid Syndrome Diarrhea in combination with somatostatin analog therapy

* Says ‍approval allows for marketing of Xermelo by co’s collaborator Ipsen in all 28 member states of EU, Norway and Iceland​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below